Belantamab (Anti-TNFRSF17 / BCMA / CD269) is a humanized monoclonal antibody directed against the B-cell maturation antigen (BCMA) found on the surface of cancer cells that can be used in the synthesis of an antibody-drug conjugate (ADC), Belantamab mafodotin. The Belantamab mafodotin, sold under the brand name Blenrep, is a monoclonal antibody Belantamab conjugated with a cytotoxic agent (MMAF)through a linker. It’s used for treating relapsed and refractory multiple myeloma, particularly in patients who have undergone at least four prior therapies. This biosimilar antibody is used for research only. MW: 145.5 KD.
Product Details |
Species Reactivity | Human |
---|
Host/Isotype | Human IgG1 |
---|
Class | Monoclonal |
---|
Type | Recombinant Antibody |
---|
Immunogen | Human BCMA |
---|
Clone | Belantamab biosimilar |
---|
Conjugate | Unconjugated |
---|
Purity | 99% |
---|
Molecular Weight | 145.5 KD |
---|
Protein Concentration | 1mg/ml |
---|
Storage Condition | Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
---|
Storage Buffer | 100mM Pro-Ac, 20mM Arg-Ac, pH 5.0 |